Systemic chemotherapy combined with anti-epidermal growth factor receptor antibody therapy for RAS wild-type appendiceal signet-ring cell carcinoma: a series of three cases

被引：1

作者：

Hirose, Suguru ^{[1
]}

Enami, Chiaki ^{[1
]}

Kawamatsu, Natsumi ^{[2
]}

Ito, Yoshimi ^{[1
]}

Onoda, Tsubasa ^{[1
]}

Sugiyama, Yutaro ^{[1
]}

Suzuki, Hirosumi ^{[1
]}

Nagafuchi, Miho ^{[1
]}

Ikeda, Takafumi ^{[1
]}

Niisato, Yusuke ^{[1
]}

Yamada, Takeshi ^{[1
]}

Yamamoto, Yoshiyuki ^{[1
]}

Moriwaki, Toshikazu ^{[1
]}

Suzuki, Hideo ^{[1
]}

机构：

[1] Univ Tsukuba, Fac Med, Dept Gastroenterol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan

[2] Univ Tsukuba Hosp, Dept Pathol, Tsukuba, Ibaraki, Japan

来源：

INTERNATIONAL CANCER CONFERENCE JOURNAL | 2022年 / 11卷 / 01期

关键词：

Anti-epidermal growth factor receptor antibody; Appendiceal carcinoma; RAS status; Signet-ring cell carcinoma; Systemic chemotherapy; METASTATIC COLORECTAL-CANCER; THYMIDYLATE SYNTHASE; OXALIPLATIN; SURVIVAL; FLUOROURACIL; ADENOCARCINOMA; COMBINATION; LEUCOVORIN; MUTATIONS; ERCC1;

D O I：

10.1007/s13691-021-00507-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The effect of anti-epidermal growth factor receptor (EGFR) antibody-containing chemotherapy on appendiceal signet-ring cell carcinoma (SRCC) remains unknown. Herein, we report three patients, diagnosed as having synchronous metastases, who underwent this treatment for unresectable appendiceal SRCC with RAS wild type. Cases 1, 2, and 3 received FOLFOX with panitumumab, FOLFOX with cetuximab, and FOLFIRI with cetuximab, respectively, and their progression-free survival were 6.2, 7.2, and 18.7 months, respectively. The subsequent anti-vascular endothelial growth factor antibody-containing therapy was ineffective, and their overall survival was 8.2, 11.4, and 22.9 months, respectively. The anti-EGFR antibody-containing chemotherapy showed moderate efficacy for appendiceal SRCC. Further studies including molecular analysis should be needed.

引用

页码：17 / 22

页数：6

共 35 条

[31]

Tung SY, 1996, AM J GASTROENTEROL, V91, P2195

[32] Importance of Histologic Subtype in the Staging of Appendiceal Tumors [J].

Turaga, Kiran K. ;

Pappas, Sam G. ;

Gamblin, T. Clark .

ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (05) :1379-1385

[33] Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen [J].

Van Cutsem, Eric ;

Tabernero, Josep ;

Lakomy, Radek ;

Prenen, Hans ;

Prausova, Jana ;

Macarulla, Teresa ;

Ruff, Paul ;

van Hazel, Guy A. ;

Moiseyenko, Vladimir ;

Ferry, David ;

McKendrick, Joe ;

Polikoff, Jonathan ;

Tellier, Alexia ;

Castan, Remi ;

Allegra, Carmen .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3499-3506

[34] Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer [J].

Van Cutsem, Eric ;

Koehne, Claus-Henning ;

Hitre, Erika ;

Zaluski, Jerzy ;

Chien, Chung-Rong Chang ;

Makhson, Anatoly ;

D'Haens, Geert ;

Pinter, Tamas ;

Lim, Robert ;

Bodoky, Gyoergy ;

Roh, Jae Kyung ;

Folprecht, Gunnar ;

Ruff, Paul ;

Stroh, Christopher ;

Tejpar, Sabine ;

Schlichting, Michael ;

Nippgen, Johannes ;

Rougier, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (14) :1408-1417

[35]

Yoshizawa Junichi, 2013, Nihon Shokakibyo Gakkai Zasshi, V110, P1934

← 1 2 3 4 →